

Remarks

Upon entry of the foregoing amendment, claims 1-11 and 16-24 are pending in the application, with claims 1, 11 and 17-24 being the independent claims. Claims 12-15 and 25-27 are sought to be cancelled without prejudice to or disclaimer of the subject matter therein. These changes introduce no new matter, and their entry is respectfully requested.

Applicant seeks to amend the "Cross-Reference to Related Applications" to insert therein reference to the International Application, of which the present application is the U.S. National Phase, to state the relationship of the present application with the priority application, in accordance with 37 C.F.R. § 1.78, and to ensure that the priority claim accords with the Paris convention and PCT Rule 4.10. These amendments do not introduce new matter.

Applicant also seeks to remove from the "Cross-Reference to Related Applications" the claim to priority to PCT/US02/34419 and U.S. Application No. 09/984,664, in accordance with the Paris convention and PCT Rule 4.10, but seeks to preserve the incorporation by reference to these applications, which were incorporated by reference in the International Application. Thus, this amendment introduces no new matter.

Amendment to the specification is also sought to recite SEQ ID NOs, in compliance with 37 C.F.R. § 1.821. These amendments do not introduce new matter.

Deletion of the sequence listing and replacement with the substitute sequence listing is sought to comply with 37 C.F.R. §§ 1.821-1.825 and does not introduce new matter. SEQ ID NO:1 is recited in originally filed paragraph [0397], SEQ ID NOs: 2-5

are found in originally filed Figure 11, SEQ ID NOs: 6 and 7 are found in originally filed Figure 12, SEQ ID NOs: 8-10 are found in originally filed Figure 13, SEQ ID NOs: 11 and 12 are found in originally filed Figure 17, SEQ ID NOs: 13-16 are found in originally filed Figure 23, SEQ ID NO: 17 is found in originally filed Figure 27, and SEQ ID NOs: 18-21 are found in originally-filed Figure 30. Accordingly, the sequences recited in the substitute sequence listing include no new matter. 37 C.F.R. § 1.825. In accordance with 37 C.F.R. § 1.825 the paper and computer-readable copies of the substitute sequence listing submitted herewith are the same.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicant believes the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Simon J. Elliott
Agent for Applicant
Registration No. 54,083

Date: October 3, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600